

Establishing risk of vision loss in Leber hereditary optic neuropathy

M. Isabel G. Lopez Sanchez,^{1,2} Lisa S. Kearns,¹ Sandra E. Staffieri,^{1,2} Linda Clarke,¹ Myra B. McGuinness,^{1,3} Wafaa Meteoukki,¹ Sona Samuel,¹ Jonathan B. Ruddle,^{1,2} Celia Chen,⁴ Clare L. Fraser,⁵ John Harrison,⁶ Alex W. Hewitt,^{1,7} Neil Howell,⁸ and David A. Mackey^{7,9,*}

Summary

We conducted an updated epidemiological study of Leber hereditary optic neuropathy (LHON) in Australia by using registry data to establish the risk of vision loss among different LHON mutations, sex, age at onset, and mitochondrial haplogroup. We identified 96 genetically unrelated LHON pedigrees, including 56 unpublished pedigrees, and updated 40 previously known pedigrees, comprising 620 affected individuals and 4,948 asymptomatic carriers. The minimum prevalence of vision loss due to LHON in Australia in 2020 was one in 68,403 individuals. Although our data confirm some well-established features of LHON, the overall risk of vision loss among those with a LHON mutation was lower than reported previously—17.5% for males and 5.4% for females. Our findings confirm that women, older adults, and younger children are also at risk. Furthermore, we observed a higher incidence of vision loss in children of affected mothers as well as in children of unaffected women with at least one affected brother. Finally, we confirmed our previous report showing a generational fall in prevalence of vision loss among Australian men. Higher reported rates of vision loss in males with a LHON mutation are not supported by our work and other epidemiologic studies. Accurate knowledge of risk is essential for genetic counseling of individuals with LHON mutations. This knowledge could also inform the detection and validation of potential biomarkers and has implications for clinical trials of treatments aimed at preventing vision loss in LHON because an overestimated risk may lead to an underpowered study or a false claim of efficacy.

Introduction

Leber hereditary optic neuropathy (LHON [MIM: 535000]) is a primary mitochondrial disease characterized by optic atrophy due to degeneration of retinal ganglion cells in the retina.¹ LHON is caused by point mutations in mitochondrial DNA (mtDNA) genes encoding subunits of oxidative phosphorylation complex I. Most people with vision loss from LHON harbor one of three primary LHON mutations in MT-ND4 (m.11778G>A [p.Arg340His]),² MT-ND6 (m.14484T>C [p.Met64Val]),^{3,4} or MT-ND1 (m.3460G>A [p.Ala52Thr]).^{5,6} The presence of a LHON mutation is not in itself sufficient to cause vision loss. Studies have suggested an association between mtDNA haplogroup and risk of vision loss.^{7–9} Similarly, some environmental risk factors, including tobacco smoking, heavy alcohol consumption, and exposure to toxic drugs, may trigger vision loss in some LHON mutation carriers.^{10–12} Additional genetic risk factors remain unidentified, and it is currently unknown why only some carriers lose vision.¹³

A risk of vision loss of 50% among men who carry a LHON mutation is still widely cited, although this is most likely a remnant from the time when LHON was thought to be an X-linked recessive disease.¹⁴ Furthermore,

asymptomatic men are likely to be missed in pedigree ascertainment, resulting in an over-estimation of the risk of vision loss. In studies with thorough genealogist-supported pedigree ascertainment, a lower risk of vision loss among male mutation carriers has been observed.^{15–17} The risk of vision loss for females is lower than for males, and a recent study suggested there is a steady lifetime risk for female carriers rather than a peak risk in early adult life as seen in male carriers.¹⁸ In addition, some families appear to have markedly higher or lower penetrance or decreased penetrance over successive generations.^{19,20}

Communication about genetic risks is an important component of genetic counseling. The 2006 definition of genetic counseling states that the process integrates “Interpretation of family and medical histories to assess the chance of disease occurrence or recurrence.²¹” Thus more accurate knowledge of risk of LHON-associated vision loss is critical. Genetic counseling promotes informed choices in view of risk assessment, family goals, and ethical and personal values. It also offers support and assists the person with vision loss and their family with effective coping strategies for dealing with increased levels of uncertainty associated with LHON. Vision loss from LHON is catastrophic and with a lack of effective treatments some

¹Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, 32 Gisborne Street, East Melbourne, 3002 VIC, Australia; ²Ophthalmology, University of Melbourne, Department of Surgery, Parkville, 3010 VIC, Australia; ³Melbourne School of Population and Global Health, University of Melbourne, Melbourne, 3010 VIC, Australia; ⁴Flinders Medical Centre, Flinders University, Bedford Park, 5042 SA, Australia; ⁵Save Sight Institute, Discipline of Ophthalmology, Faculty of Health and Medicine, The University of Sydney, 2000 NSW, Australia; ⁶Department of Ophthalmology, Royal Brisbane and Women’s Hospital, Herston, 4029 QLD, Australia; ⁷School of Medicine, Menzies Institute for Medical Research, University of Tasmania, Hobart, 7005 TAS, Australia; ⁸Matrilinex LLC, San Diego, CA 92122, USA; ⁹Centre for Ophthalmology and Visual Science, Lions Eye Institute, University of Western Australia, 2 Verdun Street, Nedlands, 6009 WA, Australia

*Correspondence: david.mackey@utas.edu.au

<https://doi.org/10.1016/j.ajhg.2021.09.015>

© 2021 The Author(s). This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).



individuals may consider reproductive options such as donor egg IVF and mitochondrial donation—where legally available—to reduce their risk of having an affected child with LHON. Accurate information on the risk of vision loss would allow families to make informed choices when planning their families. Additionally, planning future clinical trials of treatments aimed at preventing vision loss in LHON will need accurate data on risk and age of vision loss because an inaccurate risk may lead to an underpowered study or a false claim of efficacy.

Here, we conducted an epidemiological and penetrance study of LHON by using a clinical register to cover the entire population of Australia. There are currently 96 LHON families in Australia, 40 of whom had been published in our previous studies.^{15,22} We aimed to establish the number of affected and asymptomatic individuals for each pedigree to estimate prevalence and penetrance among different LHON mutations, sex, age at onset, and mitochondrial haplogroup. Furthermore, we aimed to determine the risk of vision loss for offspring of affected mothers and among nieces and nephews of affected men. Finally, we investigated whether the rate of vision loss among men from the largest LHON pedigree in Australia had continued to fall.

Subjects and methods

Ethics

This study was conducted in accordance with the revised Declaration of Helsinki and following the Australian National Health and Medical Research Council statement of ethical conduct in research involving humans. Ethical approval was obtained from the Royal Victorian Eye and Ear Hospital Human Research Ethics Committee and University of Western Australia Human Research Ethics Committee. Written, informed consent was provided by all individuals who provided blood or saliva samples.

Participants

A registry of individuals with LHON hosted by the Royal Victorian Eye and Ear Hospital Ocular Diagnostic Clinic (Melbourne) was established in 1994. Individuals seen at this clinic and those referred to Professor David Mackey from ophthalmologists across Australia since 1990 were included on the registry (see detailed [supplemental subjects and methods](#) for further details). The presence of a LHON mutation was determined during clinical genetic testing by a National Association of Testing Authorities-accredited laboratory and confirmed for all pedigrees as described below. In the “affected” LHON group, individuals presented with characteristic clinical fundus changes²³ and a history of painless, acute vision loss in one eye, with the fellow eye either simultaneously or sequentially affected. Visual acuity measured in a logMAR vision chart in affected individuals ranged from 6/60 down to perception of light vision. Asymptomatic LHON mutation carriers (“carriers”) were recruited or identified from maternal lineages of affected individuals (methods for identifying lineage detailed in [supplemental subjects and methods](#)). To minimize the likelihood of including carriers who may yet lose vision, we only included carriers over 25 years old in the analysis because this is the average age of vision loss onset in LHON reported in current literature.^{16,24,25}

DNA extraction and mtDNA sequencing

Genomic DNA was extracted from peripheral whole blood via a QIAamp DNA Blood Maxi Kit (QIAGEN, Hilden, Germany) or from saliva via an Oragene DNA saliva collection kit (DNA Genotek, Ontario, Canada) according to the manufacturers’ protocols.

The presence of a LHON mutation was confirmed by polymerase chain reaction (PCR; Invitrogen; primers used are included in [Table S1](#)) and Sanger sequencing, whole mtDNA sequencing,²⁶ or MitoChip high-throughput sequencing microarray,²⁷ followed by alignment against the mtDNA revised Cambridge Reference Sequence (GenBank: NC_012920.1). In homoplasmic pedigrees, maternal relatives of an individual carrying a homoplasmic pathogenic mutation are also carriers of the same mutation and therefore not all maternal relatives were tested.

Mitochondrial haplogroup determination

Mitochondrial haplogroup was determined either by whole mtDNA sequencing or by PCR and Sanger sequencing of the mitochondrial D-loop hypervariable regions 1 and 2 (HV1 and HV2; primers used are included in [Table S1](#)). MtDNA haplogroup was obtained by sequence comparison with MitoMaster²⁸ or PhyloTree.²⁹ Haplogroup-defining variants identified in each pedigree sequenced are shown in [Tables S2](#) and [S3](#). Partial mtDNA control region sequencing resulted in top level haplogroup determination only.

Statistical analysis

We used number and percent to describe the distribution of mutation type, haplotype, and sex among included individuals. Age of vision loss onset among affected individuals was summarized as median, range, and interquartile range (IQR) and was compared according to sex via the Wilcoxon rank-sum test.

Because mortality data were not available for all participants, individuals aged 85 years and above on December 1, 2020 were excluded from prevalence estimates, as were those known to be deceased. Australian population estimates were derived from the 2016 census data (source: Australian Bureau of Statistics TableBuilder, accessed December 1, 2020, [web resources](#)).

Penetrance was estimated with 95% confidence intervals (CIs) as the proportion of LHON mutation carriers who manifest clinically discernible loss of vision. Penetrance was determined in each pedigree independently, and combined penetrance values were calculated for each LHON mutation and for males and females separately. For all penetrance analyses, only asymptomatic carriers over 25 years of age as of December 1, 2020 were included. However, all affected individuals were included (including those deceased or over those 85 years of age).

We used multivariable logistic regression with robust standard errors to account for intra-family correlation to investigate the association between vision loss and mtDNA haplogroup (H, J, other, or unknown), after adjusting for sex and mutation. Only a subgroup of individuals—those carrying the m.11778G>A or m.14484T>C mutations—were included in this analysis because these were the only mutations observed in combination with both J and H haplogroups.

Results

Minimum LHON prevalence in Australia

We identified 96 genetically unrelated LHON pedigrees, including 56 new pedigrees, and updated 40 previously

Table 1. Individual LHON pedigrees in Australia

	Pedigree	Mutation	Affected male	Affected female	Carrier male^a	Carrier female^a	Family penetrance^b	mtDNA haplogroup	Reference
1	ACT02	11778	1	2	0	3	50%	unknown	new
2	NSW01	11778	8	3	45	59	10%	H1n	Mackey and Buttery ¹⁵
3	NSW02	11778	8	3	68	80	7%	H	Mackey and Buttery ¹⁵
4	NSW03	11778	3	2	26	29	8%	U5a1	Mackey and Buttery ¹⁵
5	NSW04	11778	21	7	55	70	18%	J1c1	Chan et al. ²²
6	NSW05	11778	3	2	13	13	16%	unknown	Chan et al. ²²
7	NSW06	11778	9	5	12	15	34%	H4a1	Chan et al. ²²
8	NSW09	11778	8	6	14	21	28%	J1c4	new
9	NSW11	11778	2	1	4	7	21%	Y2a	new
10	NSW16	11778	1	0	3	3	14%	unknown	new
11	NSW17	11778	1	0	5	5	9%	T2f1	new
12	NSW18	11778	1	0	2	6	11%	J1c1	new
13	NSW20	11778	4	2	3	7	37%	unknown	new
14	NSW23	11778	3	0	4	7	21%	J	new
15	NSW25	11778	1	0	9	10	5%	unknown	new
16	NSW26	11778	0	2	0	5	28%	K	new
17	NZ01	11778	0	1	0	1	50%	U	Chan et al. ²²
18	NZ02	11778	7	3	14	28	19%	U5b2a	Chan et al. ²²
19	NZ03	11778	2	0	0	3	40%	J	Chan et al. ²²
20	NZ04	11778	1	0	1	3	20%	unknown	Chan et al. ²²
21	NZ05	11778	1	0	0	1	50%	unknown	Chan et al. ²²
22	NZ07	11778	1	0	0	3	25%	unknown	new
23	NZ08	11778	1	0	3	8	8%	unknown	new
24	NZ09	11778	3	0	0	2	60%	unknown	new
25	NZ12	11778	0	1	3	2	16%	H	new
26	QLD02	11778	7	2	33	40	11%	J2b1	Mackey and Buttery ¹⁵
27	QLD03	11778	1	0	9	14	4%	J1c2	Chan et al. ²²
28	QLD04	11778	1	0	3	4	12%	T2b4	Chan et al. ²²
29	QLD05	11778	0	1	6	10	6%	HV	new
30	QLD07	11778	1	0	4	9	7%	unknown	new
31	QLD09	11778	0	1	5	5	9%	unknown	new
32	QLD10	11778	1	0	6	9	6%	N	new
33	QLD11	11778	1	0	1	5	14%	W	new
34	QLD12	11778	2	1	1	6	30%	U	new
35	SAU03	11778	1	0	3	8	8%	unknown	new
36	TAS01	11778	112	27	899	1025	7%	H	Mackey and Buttery ¹⁵
37	TAS05	11778	2	0	22	21	4%	H3f	Mackey and Buttery ¹⁵

(Continued on next page)

Table 1. Continued

Pedigree	Mutation	Affected male	Affected female	Carrier male^a	Carrier female^a	Family penetrance^b	mtDNA haplogroup	Reference
38 VIC03	11778	7	0	14	23	16%	U	Mackey and Buttery ¹⁵
39 VIC04	11778	6	0	34	40	7%	H1c3	Mackey and Buttery ¹⁵
40 VIC05	11778	1	0	12	20	3%	K2a4	Mackey and Buttery ¹⁵
41 VIC06	11778	7	2	10	14	27%	H1	Mackey and Buttery ¹⁵
42 VIC07	11778	11	0	16	38	17%	I2a	Mackey and Buttery ¹⁵
43 VIC09	11778	1	0	4	6	9%	unknown	Chan et al. ²²
44 VIC10	11778	6	2	8	9	32%	J2a1a	Chan et al. ²²
45 VIC15	11778	2	0	9	9	10%	unknown	new
46 VIC17	11778	1	1	2	2	33%	J1c5a	new
47 VIC18	11778	1	1	2	2	33%	U4c1	new
48 VIC19	11778	1	0	4	8	7%	B4b1a2	Craig et al. ³¹
49 VIC21	11778	4	3	24	27	12%	H13a1a	new
50 VIC22	11778	1	0	14	21	3%	H13a1a	new
51 VIC25	11778	1	0	4	5	10%	T1a1	new
52 VIC29	11778	1	1	32	33	3%	U5a1a1	new
53 VIC31	11778	2	0	4	4	20%	J	new
54 VIC39	11778	1	0	3	4	12%	unknown	new
55 VIC40	11778	3	1	3	5	33%	unknown	new
56 VIC41	11778	1	0	0	2	33%	H	new
57 VIC43	11778	1	0	1	3	20%	K	new
58 VIC45	11778	3	0	0	4	42%	unknown	new
59 VIC46	11778	1	0	5	4	10%	B	new
60 WAU01	11778	16	5	42	55	18%	J	Mackey and Buttery ¹⁵
61 WAU02	11778	6	1	20	25	13%	K	Chan et al. ²²
62 WAU03	11778	1	0	21	39	1%	I2a	Chan et al. ²²
63 WAU04	11778	1	1	22	19	4%	H3	new
64 WAU11	11778	1	1	6	19	7%	unknown	new
65 WAU12	11778	2	0	1	6	22%	unknown	new
66 ACT01	14484	3	0	1	12	19%	J	Chan et al. ²²
67 NSW10	14484	0	1	0	1	50%	unknown	new
68 NSW12	14484	1	0	22	44	1%	K1c2	new
69 NSW15	14484	2	0	9	15	8%	U5a1a1	new
70 NSW19	14484	6	1	21	26	13%	L1b1a1	new
71 NSW24	14484	1	0	2	3	17%	unknown	new
72 NZ06	14484	1	0	3	9	8%	unknown	new
73 NZ10 ^c	14484	1	0	13	13	4%	J	new
74 NZ11	14484	1	0	5	12	6%	J	new

(Continued on next page)

Table 1. Continued

Pedigree	Mutation	Affected male	Affected female	Carrier male ^a	Carrier female ^a	Family penetrance ^b	mtDNA haplogroup	Reference
75 SAU02	14484	1	1	1	1	50%	unknown	Chan et al. ²²
76 SAU05	14484	0	1	5	15	5%	H	new
77 TAS02	14484	74	9	320	380	11%	J1c2c	Mackey and Buttery ¹⁵
78 VIC02 ^c	14484	2	4	1	3	60%	J1b1a	Mackey and Buttery ¹⁵
79 VIC08	14484	1	0	7	9	6%	J1c1	Mackey and Buttery ¹⁵
80 VIC11	14484	5	5	12	22	23%	J1c1	Chan et al. ²²
81 VIC14	14484	1	0	17	34	2%	H3c	Howell et al. ²⁶
82 VIC24	14484	1	0	3	2	17%	unknown	new
83 VIC30 ^c	14484	1	0	9	15	4%	H	new
84 VIC42	14484	1	0	7	11	5%	J	new
85 WAU7	14484	1	0	2	2	20%	unknown	new
86 NSW07	3460	1	1	2	6	20%	T	Chan et al. ²²
87 NSW14	3460	0	1	1	1	33%	unknown	new
88 TAS03	3460	3	0	45	39	3%	H5a1	Mackey and Buttery ¹⁵
89 VIC01	3460	6	3	4	11	37%	H	Mackey and Buttery ¹⁵
90 VIC28	3460	3	0	7	7	18%	H	new
91 WAU06	3460	1	0	7	8	6%	M53	new
92 WAU08	3460	2	0	7	10	10%	unknown	new
93 SAU04	4171	1	1	4	6	17%	HV0	new
94 NSW08	14482	5	2	17	30	13%	I1a	Chan et al. ²²
95 VIC20	11778+14484	1	2	15	23	7%	U5a1a1	Howell et al. ³³
96 QLD01	14484+4160	26	35	9	14	73%	U4a1a	Mackey and Buttery ¹⁵
Total		462	158	2,171	2,777			

LHON pedigrees are organized alphabetically and by LHON mutation.

^aOnly asymptomatic carriers over 25 years of age are included.

^bRounded to nearest whole percentage.

^cHeteroplasmic mutation.

known pedigrees in Australia (Table 1).^{4,22,30–35} Updated assignments of LHON matrilineal pedigrees are shown in Table S4. Among the pedigrees, 43/96 (44.8%) were sporadic cases, with only one affected person identified thus far, and 53/96 (55.2%) were familial. In total, we identified 5,568 individuals harboring LHON mutations, including 620 affected individuals (462 males and 158 females) and 4,948 matrilineal carriers (2,171 males and 2,777 females) (Table 1). After excluding known deceased individuals and people over 85 years old, 355 live individuals remained (Figure 1). This is equivalent to a minimum LHON vision loss prevalence in Australia of one in 68,403 from a population of 22,915,047.

The majority of affected individuals (400/620, 64.5%) harbored the m.11778G>A mutation, and the

m.14484T>C mutation was the next most common (126/620, 20.3%; Table 2). The m.3460G>A mutation was present in only 3.4% of affected individuals (21/620). Together, the three primary LHON mutations accounted for 88.2% of total LHON cases. Four additional pedigrees harbored either double LHON mutations (VIC20, m.11778G>A + m.14484T>C;³³ QLD01 m.14484T>C + m.4160T>C³⁰) or rare LHON mutations (NSW08, m.14482C>G;³² SAU04, m.4171C>A) (Table 2). All pedigrees harbored homoplasmic mutations, except for VIC02,³¹ VIC30, and NZ10, who harbored heteroplasmic mutations (Figure S1).

We observed the characteristic sex predominance in LHON; there were 462/620 (74.5%) affected males and 158/620 (25.5%) affected females (Table 2), resulting in a




Figure 1. Flow chart of included individuals with LHON

Previously published and new pedigrees with numbers of affected and unaffected carriers included in study.

male to female ratio of 2.92:1. The ratios of affected males to affected females for each of the primary LHON mutations were 3.4:1 (m.11778G>A), 4.7:1 (m.14484T>C), and 3.2:1 (m.3460G>A).

Vision loss penetrance due to LHON

The overall penetrance—or proportion of individuals affected by vision loss among all LHON mutation carriers in Australia—was 17.5% for males (462/2,633, 95% CI 16.1, 19.1) and 5.4% for females (158/2,935, 95% CI 4.6, 6.3) (Table 2). This indicates an overall risk of vision loss for 1 in 6 males and 1 in 20 females harboring a LHON mutation.

Penetrance was slightly variable for each of the three primary LHON mutations: m.11778G>A, 16.2% (males) and 4.3% (females); m.14484T>C, 18.4% (males) and 3.4% (females); and m.3460G>A, 18% (males) and 5.7% (females). Furthermore, penetrance was also highly variable among individual pedigrees, ranging between 1%–73% (Table 1).

It must be noted that our data include two previously described large pedigrees (TAS01 and TAS02) that together account for 35.8% (222/620) of total individuals affected with LHON in our cohort (Table 1). Furthermore, highly penetrant pedigrees included the previously described VIC02 family, which had six out of ten carriers affected by vision loss (60% penetrance), and the QLD01 family, which had 61 out of 84 maternal relatives affected by vision loss (72.6% penetrance).^{15,22,31,34,36} At least nine members of the QLD01 pedigree presented with neurological abnormalities characteristic of “LHON plus” syndrome.³⁰

Vision loss penetrance among mtDNA haplogroups

Mitochondrial haplogroup was determined in 68 out of 96 pedigrees (Table 1), as suitable DNA samples were not available for sequencing in all lineages. This is equivalent to 84.8% of affected individuals (526/620) and 94.5% of

asymptomatic carriers (4,675/4,948). Overall, 13 mtDNA haplogroups (J, H, U, K, T, I, HV, B, N, W, Y, L, and M) were identified (Tables 3 and S5). As expected, given the European ancestry of most individuals in our study, a large proportion of lineages belonged to haplogroups J (19/68; 27.9%) and H (18/68; 26.5%). However, non-European mitochondrial haplogroups, including B, M, I, and Y, were also identified, which reflects more recent immigration to Australia of families from non-European countries.

Haplotype H was most common among individuals with mutation m.11778G>A (67.7%), whereas haplotype J was more common among individuals with mutation m.14484T>C (76.9%) (Table S5).

The proportion of individuals with vision loss was similar between those with mutation m.11778G>A or m.14484T>C. However, after adjusting for sex and haplogroup, the odds of vision loss were estimated to be almost half among those with mutation m.14484T>C compared to those with m.11778G>A (adjusted odds ratio [OR] 0.57, $p = 0.001$; Table 3). Furthermore, after adjusting for sex and mutation, individuals with haplogroup J were estimated to have almost three times the odds of vision loss compared to those with haplotype H (OR 2.85, $p = 0.001$; Table 3).

Age of onset of vision loss attributable to LHON

We were able to ascertain age of vision loss in 361 out of 620 individuals with LHON mutations (Figure 2A). Across all LHON mutations, the median age at onset of vision loss was similar between males (22 years, IQR = 17–30; range 1–67) and females (21 years, IQR = 11–39; range 2–81, p value = 0.63). Age at onset of vision loss was slightly higher for females (median = 28.5 years; IQR = 18–42; range 6–81) compared to males (median = 22 years; IQR = 17–67; range 1–67) with the m.11778G>A mutation (p value = 0.07; Figure 2B). Age of vision loss onset was similar between males (median = 25 years; IQR = 18–37; range 9–65) and females (median = 21 years; IQR = 14–40; range 6–73, p value = 0.55) with the m.14484T>C mutation.

Among males, vision loss onset peaked between 15–24 years of age, accounting for 41.3% (107/259) of male affected individuals harboring one of the three primary LHON mutations. For females, the age at symptom onset was distributed evenly across all ages. Notably, 8.8% (23/259) of males and 10.1% of females (6/59) experienced vision loss at age 10 years or under, while 5.4% of males (14/259) and 11.8% of females (7/59) lost vision age 50 years or over.

Table 2. Individuals with vision loss attributable to LHON

LHON mutation	Males with vision loss/ total carriers ^a [penetrance]	Females with vision loss/total carriers ^a [penetrance]	Total individuals with vision loss/total carriers ^a [penetrance]
m.11778G>A	309/1,902 [16.2%]	91/2,084 [4.3%]	400/3,986 [10.0%]
m.14484T>C	104/564 [18.4%]	22/651 [3.4%]	126/1,215 [10.4%]
m.3460G>A	16/89 [18.0%]	5/87 [5.7%]	21/176 [11.9%]
m.4171C>A	1/5 [20.0%]	1/7 [14.3%]	2/12 [16.7%]
m.14482C>G	5/22 [22.7%]	2/32 [6.2%]	7/54 [13.0%]
m.11778G>A/m.14484T>C	1/16 [6.2%]	2/25 [8.0%]	3/41 [7.3%]
m.14484T>C/m.4160T>C	26/35 [74.3%]	35/49 [71.4%]	61/84 [72.6%]
Total	462/2,633 [17.5%]	158/2,935 [5.4%]	620/5,568 [11.1%]

^aOnly asymptomatic carriers over 25 years of age are included.

Risk of vision loss in offspring of affected women

It was reported previously that affected women have a higher incidence of affected offspring compared to asymptomatic females.^{16,37} We updated this analysis to include all Australian LHON pedigrees to date. Among the 158 affected females, 100 had children, 54 did not, and we could not obtain information on the parental status of four women. For this sub-analysis, we excluded four affected females because they were too young to have children (12 years old or younger) and six affected mothers whose children were 22 years or younger and therefore still below the average age of vision loss onset in LHON.

In total, 94 affected mothers and 281 offspring (132 males and 149 females) were included in this sub-analysis. The median number of offspring per mother was 2.5 (IQR = 2–3; range 1–10; Table S6). Across all LHON mutations, affected mothers had 93/281 affected offspring (33.1%, 95% CI 27.6, 38.9), including 49/132 males (37.1%, 95% CI 28.9, 50.0) and 44/149 females (29.5%, 95% CI 22.3,

37.5) (Table 4). This is higher than the overall penetrance of vision loss observed among all LHON mutation carriers in this cohort (17.5% for males and 5.4% for females, Table 2). Importantly, vision loss is twice as likely among offspring of affected mothers with the most common LHON mutation, m.11778G>A (Table 4).

Next, we investigated the risk of vision loss in children of an asymptomatic woman with at least one affected brother, focusing on six large LHON pedigrees—TAS01, TAS02, NSW01, NSW02, NSW04, and WAU01 (Table 5). In general, we observed a higher incidence of vision loss in children of women with at least one affected brother (pedigrees TAS01, TAS02, NSW01, and NSW02) compared to the overall incidence of vision loss in each respective pedigree. However, incidence of vision loss was higher only among nieces of affected men in the NSW04 family, and the incidence of vision loss was not increased among nephews or nieces of affected men in the WAU01 pedigree.

Table 3. Associations between mtDNA haplogroup and vision loss

	Number (%) with vision loss	Adjusted OR	Adjusted 95% CI	Adjusted p value
Total	526/5,201 (10.1%)	–	–	–
Sex				
Female	113/2,736 (4.1%)	1.00	–	–
Male	413/2,465 (16.8%)	4.81	[3.75, 6.16]	<0.001
Mutation				
11778	400/3,986 (10.0%)	1.00	–	–
14484	126/1,215 (10.4%)	0.57	[0.41, 0.79]	0.001
Haplotype				
H	208/2,797 (7.4%)	1.00	–	–
J	197/1,429 (13.8%)	2.85	[2.04, 3.99]	<0.001
Other	73/700 (10.4%)	1.73	[1.06, 2.81]	0.028
Unknown	48/275 (17.5%)	2.92	[1.77, 4.80]	<0.001

Multivariable logistic regression estimated with all listed variables as covariates and robust standard errors to account for intra-family correlation.




Figure 2. Age of onset of vision loss in individuals harboring LHON mutations

(A) Age at onset of vision loss of 361 individuals with LHON mutations. Across all LHON mutations, median age at onset of vision loss was similar between males (22 years, IQR = 17–30; range 1–67) and females (21 years, IQR = 11–39; range 2–81, p value = 0.63, Wilcoxon rank-sum test).

(B) Age at onset of vision loss among females (median = 28.5 years; IQR = 18–42; range 6–81) and males (median = 22 years; IQR = 17–67; range 1–67) with the *m.11778G>A* mutation (p value = 0.07, Wilcoxon rank-sum test).

Decrease in prevalence of vision loss over successive generations

We reported previously an apparent generational fall in rates of vision loss among men from the largest LHON pedigree in Australia, TAS01.¹⁹ We updated this pedigree with expanded genealogical information and compared it to an earlier publication by Hogg,³⁸ which was updated and reported as “pedigree 33” by Hamilton,³⁹ who also unknowingly had separate pedigrees that linked to this original one. Within two generations in Australia, the rate of adult males losing vision has dropped from 75% to below 15% and has remained around that level (Table 6). The early publications of the pedigree suggested higher rates of visual loss as many asymptomatic men were missing from the data.

Discussion

How common is vision loss from LHON?

The clinical follow-up of LHON families in Australia has been carried out since 1915, and 96 LHON families have now been identified, 40 of which were previously published,^{15,22} comprising in total 620 individuals (462 males and 158 females) affected by vision loss. The minimum prevalence of vision loss from LHON is one in 68,403 in Australia, which compares with the earlier data from North East England of one in 31,055²⁵ and more recent data from Denmark of one in 54,000.⁴⁰ Future updates on population-wide studies will enable us to compare whether findings from other well-described LHON pedigrees in the Netherlands and Finland are similar.^{16,41}

How common are the three main LHON mtDNA mutations?

The three primary LHON mutations accounted for 88.2% of total LHON cases: 64.5% *m.11778G>A* mutation, 20.3%

m.14484T>C mutation, and only 3.4% *m.3460G>A* mutation. Because some affected individuals had combined mutations, more than 90% are explained by one or more of the three main mutations. This is similar to an earlier study of 159 multigenerational LHON pedigrees from Europe and Australia (including 16 of the Australian pedigrees), where 69% were *m.11778G>A*, 14% were *m.14484T>C*, and 13% were *m.3460G>A*,³⁵ and North East England, where 60% were *m.11778G>A*, 7% were *m.14484T>C*, and 33% were *m.3460G>A*.²⁵ This is also similar to a large international study—of which 104/1,512 affected individuals were from Australia—where 69% were *m.11778G>A*, 17% were *m.14484T>C*, and 13% were *m.3460G>A*.¹⁸

How likely are LHON mtDNA mutation carriers to be affected?

The penetrance for all LHON mutation carriers was 1 in 6 males (17.5%) and 1 in 20 females (5.4%). The rate in males is lower than the 20% overall risk of vision loss previously reported in Australia in 1992, but the rate in females is slightly higher than the 4% reported.¹⁵ These findings are similar in the Dutch population, where 29% of male and 6% of female LHON mutation carriers were affected,⁴² although more recent data are required for an accurate comparison.

Importantly, the risk of vision loss was lower than the 50% (males) or 15% (females) risk commonly cited in information accessed by family members (web resources), although penetrance was highly variable among individual Australian pedigrees (1%–73%). To minimize the likelihood of including LHON mutation carriers who may yet lose vision, we only included carriers over 25 years old in our analysis. This is a potential limitation of our study because vision loss due to LHON can occur at any time in life, and therefore, our analysis may underestimate the risk of disease expression over the entire lifespan of an individual.

Table 4. Vision loss in offspring of affected women with LHON

Affected mother mutation	Males with vision loss/total male offspring ^a [penetrance]	Females with vision loss/total female offspring ^a [penetrance]	Total individuals with vision loss/total offspring ^a [penetrance]
m.11778G>A	30/87 [34.5%]	10/91 [11%]	40/178 [22%]
m.14484T>C	3/19 [15.8%]	5/21 [23.8%]	8/40 [20%]
m.3460G>A	0/1 [N/A]	1/3 [33.3%]	1/4 [25%]
m.14484T>C/m.4160T>C	15/24 [62.5%]	27/32 [84.4%]	42/56 [75%]
m.14482C>G	1/1 [100%]	1/2 [50%]	2/3 [66.6%]
Total	49/132 [37.1%]	44/149 [29.5%]	93/281 [33.1%]

N/A, not applicable.

^aOnly asymptomatic carriers over 25 years of age are included.

Our study aimed to fully ascertain all at-risk unaffected male adults within pedigrees. The often-quoted 50% risk comes from the early period of pedigree ascertainment where LHON was presumed to be X-linked—prior to its separation from autosomal dominant optic atrophy by Kjer⁴³ and prior to recognition of its mitochondrial transmission.⁴⁴ For most of our pedigrees, being able to confidently quote a much lower and more accurate risk figure can help reduce anxiety within the whole family. However, we acknowledge it may be difficult to persuade ophthalmologists and geneticists to stop quoting 50% risk of vision loss among males. With large families, the members should be informed of the actual risk within their own family where possible.

How likely are women to be affected?

LHON predominantly affects males, and we observed a male to female ratio of 2.92:1 with 158/620 (25%) affected females. This is similar to the latest reported ratio in sporadic LHON cases in Australia of 2.67:1²² and lower than the ratio of 5:1 in 291 familial LHON cases reported previously.¹⁵

However, our earlier report¹⁵ noted that 31/135 (23%) living blind individuals were female, which is close to 25% in the current paper. This correlates with the 3:1 male to female ratio found in an international audit of LHON,¹⁸ again noting that 104/1,512 of these affected individuals were from Australia and thus counted in both studies. Interestingly, both this current study (Figure 2A) and the results published by Poincenot (2020)¹⁸ show the lack of a female early adult peak in rate of vision loss. Women may lose vision at any age, and although other causes of vision loss can occur, LHON should always be considered when an adult woman in a LHON pedigree loses vision.

Does having a close family member affected (mother or uncle) increase a family member's risk of losing vision?

A previous analysis of vision loss in offspring of affected women in Australian and Dutch pedigrees suggested a higher rate, notably in females.³⁷ In the Dutch population, children of affected mothers had a higher incidence of vision loss (53% male and 23% female offspring) compared to children of unaffected mothers (27% male and 5%

Table 5. Vision loss in children of asymptomatic women with at least one affected brother in representative LHON families

Sibship analysis within pedigree	Males with vision loss/total male offspring ^a [penetrance]	Females with vision loss/total female offspring ^a [penetrance]	Total individuals with vision loss/total offspring ^a [penetrance]
TAS01	48/289 [16.6%]	13/278 [4.7%]	61/575 [10.8%]
<i>TAS01 (complete)</i>	<i>112/1,011 [11.1%]</i>	<i>27/1,052 [2.6%]</i>	<i>139/2,063 [6.7%]</i>
TAS02	45/129 [34.9%]	6/149 [4.0%]	51/278 [18.3%]
<i>TAS02 (complete)</i>	<i>74/394 [18.8%]</i>	<i>9/389 [2.3%]</i>	<i>83/783 [10.6%]</i>
NSW01	2/9 [22.2%]	1/8 [12.5%]	3/17 [17.6%]
<i>NSW01 (complete)</i>	<i>8/53 [15.1%]</i>	<i>3/62 [4.8%]</i>	<i>11/115 [9.6%]</i>
NSW02	3/15 [20.0%]	0/17 [N/A]	3/32 [9.4%]
<i>NSW02 (complete)</i>	<i>8/76 [10.5%]</i>	<i>3/83 [3.6%]</i>	<i>11/159 [6.9%]</i>
NSW04	5/33 [15.1%]	6/43 [14.0%]	11/76 [14.5%]
<i>NSW04 (complete)</i>	<i>21/76 [27.6%]</i>	<i>7/77 [9.1%]</i>	<i>28/153 [18.3%]</i>
WAU01	5/20 [25.0%]	1/29 [3.4%]	6/49 [12.2%]
<i>WAU01 (complete)</i>	<i>16/58 [27.6%]</i>	<i>5/60 [8.3%]</i>	<i>21/118 [17.8%]</i>

Penetrance for each complete pedigree (from Table 1) is included in italics to facilitate direct comparison.

^aOnly asymptomatic carriers over 25 years of age are included.

Table 6. Falling rate of vision loss among males from the largest Australian LHON pedigree, TAS01

Generation with earliest year of male birth	This study (full genealogical ascertainment)	Mackey and Howell ¹⁹	Hamilton ³⁹ "pedigree 33"	Hogg ³⁸
IV b1804	3 of 4 (75%)	3 of 4 (75%)	3 of 3 (100%) ^a	3 of 3 (100%) ^b
V b1823	4 of 19 (21%)	4 of 17 (24%)	5 of 5 (100%)	3 of 15 (20%)
VI b1844	13 of 105 (12%)	12 of 86 (14%)	7 of 18 (39%)	N/A
VII	27 of 202 (13%)	27	7 of 21 (33%)	N/A
VIII	26 of 180 (14%)	22	N/A	N/A
IX	26 of 229 (11%)	21	N/A	N/A
X	11 of 209 (5%)	2	N/A	N/A

Number of individuals with vision loss and penetrance (%) are shown for each generation. N/A, not applicable.

^aTwo sub-matriarchs missing.

^bOne missing unaffected man who moved to Melbourne.

female offspring).⁴² In our Australian study, children of affected mothers had a higher incidence of vision loss (37% male and 29.5% female offspring) than the overall incidence of vision loss observed among all LHON mutation carriers (17.5% male and 5.4% female). The increased risk in daughters is of concern, but it is still more likely that the daughter will never lose vision in her lifetime.

Similarly, we observed a higher incidence of vision loss in children of asymptomatic women with at least one affected brother in some pedigrees. Focusing on six large pedigrees, we compared it to the overall incidence of vision loss in each respective pedigree (nephew risk%:family-male-risk%). The nephew risk was higher in four families, TAS01 (16.6%:11.1%), TAS02 (34.9%: 18.8%), NSW01 (22.2%: 15.1%), and NSW02 (20.0%:10.5%), but not in two families, NSW04 (15.1%:27.6%) and WAU01 (25%:27.6%). The incidence of vision loss was higher only among nieces of affected men in the NSW04 family, and the incidence of vision loss was not increased among nephews or nieces of affected men in the WAU01 pedigree.

The fall in vision loss among males from the largest LHON pedigree in Australia¹⁹ could be explained by a reduction in environmental triggers over time or, alternatively, by a dilution of a background genetic risk with subsequent generations. We have noted high- and low-risk branches within this family previously.⁴⁵ A similar decrease in prevalence of vision loss over successive generations has been observed in a large Italian/Brazilian pedigree with the m.11778G>A mutation.⁴⁶

Finding modifier genes to predict risk of vision loss

Although the proportion of individuals with vision loss was similar between those with the m.11778G>A or m.14484T>C mutations, after adjusting for sex and mtDNA haplogroup, the odds of vision loss were almost half as low among those with the m.14484T>C mutation compared to those with m.11778G>A. Furthermore, it was reported previously that vision loss is more frequent among individuals harboring the m.11778G>A mutation and mtDNA haplogroup J.⁸ We previously reported very low penetrance in family VIC14 with the m.14484T>C

mutation on a background of haplogroup H and that the m.14484T>C mutation is under-represented among haplogroup H mtDNAs that carry a LHON mutation.⁷ In the current study, individuals with haplogroup J were estimated to have almost three times the odds of vision loss compared to those with haplotype H. For genetic counseling purposes, determining the haplogroup may help explain a large, low penetrance pedigree.

There is currently a large amount of work being conducted on the genetics of the optic nerve structure and glaucoma, which may identify some overlapping genetic risk factors for LHON as well as potential new neuroprotective treatments,⁴⁷ and potential biomarkers in LHON are under investigation.¹³ Nuclear genetic modifiers that may also influence LHON penetrance have been identified and require further research.^{48,49}

Many families will often experience stress and anxiety when informed they carry a LHON mutation. If high-risk genetic backgrounds are shown to increase risk of vision loss from LHON, then deciding whether or not to be informed about this risk will be complex given the inability to predict the onset of vision loss and that there are no effective interventions currently. This has been the experience in Huntington disease (HD), which suggests that 80% of those at risk for HD choose not to undergo a predictive genetic test.⁵⁰ Thus, genetic counseling for those affected by vision loss from LHON and their families is imperative.

Conclusion

We have established and maintain an Australian network of researchers, clinicians, and the LHON community that has guaranteed that families with a known or putative LHON diagnosis have been brought to our attention since 1990. Our study represents, if not all, at least the overwhelming majority of LHON families in Australia. Accurate knowledge of risk is essential for genetic counseling within individual pedigrees and to provide access to existing and experimental treatments, such as idebenone or gene therapy, to prevent vision loss in individuals at particularly high risk. Accurate assessment of risk of vision loss

will also be important in guiding families to assisted reproductive technologies such as mitochondrial donation. This knowledge could also assist in the detection and validation of potential biomarkers in LHON and may also inform clinical trial design, as an overestimated risk may lead to an underpowered study or a false claim of efficacy.

Data and code availability

The published article includes all datasets generated or analyzed during this study.

Supplemental information

Supplemental information can be found online at <https://doi.org/10.1016/j.ajhg.2021.09.015>.

Acknowledgments

We thank and acknowledge the referring clinicians and all the Australian LHON families who participated in this work, including the LHON Facebook support group, and Maree Ring for her extensive genealogical work with LHON pedigrees over three decades. We acknowledge the financial support provided by the Ophthalmic Research Institute of Australia, the Mito Foundation, and Australia's National Health and Medical Research Council (1116360 and 1023911). The Centre for Eye Research Australia (CERA) receives Operational Infrastructure Support from the Victorian Government.

Declaration of interests

The authors declare no competing interests.

Received: July 12, 2021

Accepted: September 27, 2021

Published: October 19, 2021

Web resources

Australian bureau of statistics, <https://abs.gov.au/>

LHON information (UK), lhonsociety.org

LHON information (USA), lhon.org

References

1. Lopez Sanchez, M.I., Crowston, J.G., Mackey, D.A., and Trounce, I.A. (2016). Emerging Mitochondrial Therapeutic Targets in Optic Neuropathies. *Pharmacol. Ther.* *165*, 132–152.
2. Wallace, D.C., Singh, G., Lott, M.T., Hodge, J.A., Schurr, T.G., Lezza, A.M., Elsas, L.J., 2nd, and Nikoskelainen, E.K. (1988). Mitochondrial DNA mutation associated with Leber's hereditary optic neuropathy. *Science* *242*, 1427–1430.
3. Johns, D.R., Neufeld, M.J., and Park, R.D. (1992). An ND-6 mitochondrial DNA mutation associated with Leber hereditary optic neuropathy. *Biochem. Biophys. Res. Commun.* *187*, 1551–1557.
4. Mackey, D., and Howell, N. (1992). A variant of Leber hereditary optic neuropathy characterized by recovery of vision and by an unusual mitochondrial genetic etiology. *Am. J. Hum. Genet.* *51*, 1218–1228.
5. Howell, N., Bindoff, L.A., McCullough, D.A., Kubacka, I., Poulton, J., Mackey, D., Taylor, L., and Turnbull, D.M. (1991). Leber hereditary optic neuropathy: identification of the same mitochondrial ND1 mutation in six pedigrees. *Am. J. Hum. Genet.* *49*, 939–950.
6. Huoponen, K., Vilkki, J., Aula, P., Nikoskelainen, E.K., and Savontaus, M.L. (1991). A new mtDNA mutation associated with Leber hereditary optic neuroretinopathy. *Am. J. Hum. Genet.* *48*, 1147–1153.
7. Howell, N., Herrnstadt, C., Shults, C., and Mackey, D.A. (2003). Low penetrance of the 14484 LHON mutation when it arises in a non-haplogroup J mtDNA background. *Am. J. Med. Genet. A.* *119A*, 147–151.
8. Hudson, G., Carelli, V., Spruijt, L., Gerards, M., Mowbray, C., Achilli, A., Pyle, A., Elson, J., Howell, N., La Morgia, C., et al. (2007). Clinical expression of Leber hereditary optic neuropathy is affected by the mitochondrial DNA-haplogroup background. *Am. J. Hum. Genet.* *81*, 228–233.
9. Torroni, A., Petrozzi, M., D'Urbano, L., Sellitto, D., Zeviani, M., Carrara, F., Carducci, C., Leuzzi, V., Carelli, V., Barboni, P., et al. (1997). Haplotype and phylogenetic analyses suggest that one European-specific mtDNA background plays a role in the expression of Leber hereditary optic neuropathy by increasing the penetrance of the primary mutations 11778 and 14484. *Am. J. Hum. Genet.* *60*, 1107–1121.
10. Kirkman, M.A., Yu-Wai-Man, P., Korsten, A., Leonhardt, M., Dimitriadis, K., De Co, I.E., Klopstock, T., and Chinnery, P.F. (2009). Gene-environment interactions in Leber hereditary optic neuropathy. *Brain* *132*, 2317–2326.
11. Mackey, D.A., Fingert, J.H., Luzhansky, J.Z., McCluskey, P.J., Howell, N., Hall, A.J., Pierce, A.B., and Hoy, J.F. (2003). Leber's hereditary optic neuropathy triggered by antiretroviral therapy for human immunodeficiency virus. *Eye (Lond.)* *17*, 312–317.
12. Seo, J.H., Hwang, J.M., and Park, S.S. (2010). Antituberculosis medication as a possible epigenetic factor of Leber's hereditary optic neuropathy. *Clin. Exp. Ophthalmol.* *38*, 363–366.
13. Lopez Sanchez, M.I.G., Van Bergen, N.J., Kearns, L.S., Ziemann, M., Liang, H., Hewitt, A.W., Mackey, D.A., and Trounce, I.A. (2020). OXPHOS bioenergetic compensation does not explain disease penetrance in Leber hereditary optic neuropathy. *Mitochondrion* *54*, 113–121.
14. Vilkki, J., Ott, J., Savontaus, M.L., Aula, P., and Nikoskelainen, E.K. (1991). Optic atrophy in Leber hereditary optic neuroretinopathy is probably determined by an X-chromosomal gene closely linked to DXS7. *Am. J. Hum. Genet.* *48*, 486–491.
15. Mackey, D.A., and Buttery, R.G. (1992). Leber hereditary optic neuropathy in Australia. *Aust. N. Z. J. Ophthalmol.* *20*, 177–184.
16. Puomila, A., Hämäläinen, P., Kivioja, S., Savontaus, M.L., Kouvumäki, S., Huoponen, K., and Nikoskelainen, E. (2007). Epidemiology and penetrance of Leber hereditary optic neuropathy in Finland. *Eur. J. Hum. Genet.* *15*, 1079–1089.
17. Qu, J., Zhou, X., Zhang, J., Zhao, F., Sun, Y.H., Tong, Y., Wei, Q.P., Cai, W., Yang, L., West, C.E., and Guan, M.X. (2009). Extremely low penetrance of Leber's hereditary optic neuropathy in 8 Han Chinese families carrying the ND4 G11778A mutation. *Ophthalmology* *116*, 558–564.e3.
18. Poincenot, L., Pearson, A.L., and Karanjia, R. (2020). Demographics of a Large International Population of Patients Affected by Leber's Hereditary Optic Neuropathy. *Ophthalmology* *127*, 679–688.

19. Mackey, D., and Howell, N. (1994). Tobacco amblyopia. *Am. J. Ophthalmol.* *117*, 817–819.
20. Sadun, A.A., Carelli, V., Salomao, S.R., Berezovsky, A., Quiros, P.A., Sadun, F., DeNegri, A.M., Andrade, R., Moraes, M., Passos, A., et al. (2003). Extensive investigation of a large Brazilian pedigree of 11778/haplogroup J Leber hereditary optic neuropathy. *Am. J. Ophthalmol.* *136*, 231–238.
21. Resta, R., Biesecker, B.B., Bennett, R.L., Blum, S., Hahn, S.E., Strecker, M.N., Williams, J.L.; and National Society of Genetic Counselors' Definition Task Force (2006). A new definition of Genetic Counseling: National Society of Genetic Counselors' Task Force report. *J. Genet. Couns.* *15*, 77–83.
22. Chan, C., Mackey, D.A., and Byrne, E. (1996). Sporadic Leber hereditary optic neuropathy in Australia and New Zealand. *Aust. N. Z. J. Ophthalmol.* *24*, 7–14.
23. Nikoskelainen, E., Hoyt, W.F., and Nummelin, K. (1983). Ophthalmoscopic findings in Leber's hereditary optic neuropathy. II. The fundus findings in the affected family members. *Arch. Ophthalmol.* *101*, 1059–1068.
24. Newman, N.J., Lott, M.T., and Wallace, D.C. (1991). The clinical characteristics of pedigrees of Leber's hereditary optic neuropathy with the 11778 mutation. *Am. J. Ophthalmol.* *111*, 750–762.
25. Yu-Wai-Man, P., Griffiths, P.G., Brown, D.T., Howell, N., Turnbull, D.M., and Chinnery, P.F. (2003). The epidemiology of Leber hereditary optic neuropathy in the North East of England. *Am. J. Hum. Genet.* *72*, 333–339.
26. Howell, N., Oostra, R.J., Bolhuis, P.A., Spruijt, L., Clarke, L.A., Mackey, D.A., Preston, G., and Herrnstadt, C. (2003). Sequence analysis of the mitochondrial genomes from Dutch pedigrees with Leber hereditary optic neuropathy. *Am. J. Hum. Genet.* *72*, 1460–1469.
27. Maitra, A., Cohen, Y., Gillespie, S.E., Mambo, E., Fukushima, N., Hoque, M.O., Shah, N., Goggins, M., Califano, J., Sidransky, D., and Chakravarti, A. (2004). The Human MitoChip: a high-throughput sequencing microarray for mitochondrial mutation detection. *Genome Res.* *14*, 812–819.
28. Lott, M.T., Leipzig, J.N., Derbeneva, O., Xie, H.M., Chalkia, D., Sarmady, M., Procaccio, V., and Wallace, D.C. (2013). mtDNA Variation and Analysis Using Mitomap and Mitomaster. *Curr. Protoc. Bioinformatics* *44*, 1.23.21–26.
29. van Oven, M., and Kayser, M. (2009). Updated comprehensive phylogenetic tree of global human mitochondrial DNA variation. *Hum. Mutat.* *30*, E386–E394.
30. Bursle, C., Riney, K., Stringer, J., Moore, D., Gole, G., Kearns, L.S., Mackey, D.A., and Coman, D. (2018). Leber Hereditary Optic Neuropathy and Longitudinally Extensive Transverse Myelitis. *JIMD Rep.* *42*, 53–60.
31. Craig, J.E., Hewitt, A.W., Dimasi, D.P., Howell, N., Toomes, C., Cohn, A.C., and Mackey, D.A. (2006). The role of the Met98Lys optineurin variant in inherited optic nerve diseases. *Br. J. Ophthalmol.* *90*, 1420–1424.
32. Howell, N., Bogolin, C., Jamieson, R., Marendra, D.R., and Mackey, D.A. (1998). mtDNA mutations that cause optic neuropathy: how do we know? *Am. J. Hum. Genet.* *62*, 196–202.
33. Howell, N., Miller, N.R., Mackey, D.A., Arnold, A., Hermstadt, C., Williams, I.M., and Kubacka, I. (2002). Lightning strikes twice: Leber hereditary optic neuropathy families with two pathogenic mtDNA mutations. *J. Neuroophthalmol.* *22*, 262–269.
34. Mackey, D.A. (1994). Three subgroups of patients from the United Kingdom with Leber hereditary optic neuropathy. *Eye (Lond.)* *8*, 431–436.
35. Mackey, D.A., Oostra, R.J., Rosenberg, T., Nikoskelainen, E., Bronte-Stewart, J., Poulton, J., Harding, A.E., Govan, G., Bolhuis, P.A., and Norby, S. (1996). Primary pathogenic mtDNA mutations in multigeneration pedigrees with Leber hereditary optic neuropathy. *Am. J. Hum. Genet.* *59*, 481–485.
36. Hewitt, A.W., Poulsen, J.P., Alward, W.L., Bennett, S.L., Budde, W.M., Cooper, R.L., Craig, J.E., Fingert, J.H., Foster, P.J., Garway-Heath, D.F., et al. (2007). Heritable features of the optic disc: a novel twin method for determining genetic significance. *Invest. Ophthalmol. Vis. Sci.* *48*, 2469–2475.
37. Mackey, D. (1993). Blindness in offspring of women blinded by Leber's hereditary optic neuropathy. *Lancet* *341*, 1020–1021.
38. Hogg, G.H. (1915). Leber's disease. *Medical Journal of Australia* *1*, 253, 253.
39. Hamilton, J.B. (1938). The significance of heredity in ophthalmology. Preliminary survey of hereditary eye diseases in tasmania. *Br. J. Ophthalmol.* *22*, 129–148.
40. Rosenberg, T., Nørby, S., Schwartz, M., Saillard, J., Magalhães, P.J., Leroy, D., Kann, E.C., and Duno, M. (2016). Prevalence and Genetics of Leber Hereditary Optic Neuropathy in the Danish Population. *Invest. Ophthalmol. Vis. Sci.* *57*, 1370–1375.
41. Vansenus, A.H. (1963). Leber's disease in the netherlands. *Doc. Ophthalmol.* *17*, 1–162.
42. Oostra, R.J., Kemp, S., Bolhuis, P.A., and Bleeker-Wagemakers, E.M. (1996). No evidence for 'skewed' inactivation of the X-chromosome as cause of Leber's hereditary optic neuropathy in female carriers. *Hum. Genet.* *97*, 500–505.
43. Kjer, P. (1956). Hereditary infantile optic atrophy with dominant transmission; preliminary report. *Dan. Med. Bull.* *3*, 135–141.
44. Bell, J. (1931). Hereditary Optic Atrophy Leber's Disease: By Julia Bell. With Frontispiece Portrait of Leber and Pedigree Plates 48-63, Figs (University Press), pp. 704–941.
45. Howell, N., and Mackey, D.A. (1998). Low-penetrance branches in matrilineal pedigrees with Leber hereditary optic neuropathy. *Am. J. Hum. Genet.* *63*, 1220–1224.
46. Sadun, A.A., Carelli, V., Salomao, S.R., Berezovsky, A., Quiros, P., Sadun, F., DeNegri, A.M., Andrade, R., Schein, S., and Belfort, R. (2002). A very large Brazilian pedigree with 11778 Leber's hereditary optic neuropathy. *Trans. Am. Ophthalmol. Soc.* *100*, 169–178, discussion 178–179.
47. Gharahkhani, P., Jorgenson, E., Hysi, P., Khawaja, A.P., Pendergrass, S., Han, X., Ong, J.S., Hewitt, A.W., Segrè, A.V., Rouhana, J.M., et al. (2021). Genome-wide meta-analysis identifies 127 open-angle glaucoma loci with consistent effect across ancestries. *Nat. Commun.* *12*, 1258.
48. Stenton, S.L., Sheremet, N.L., Catarino, C.B., Andreeva, N.A., Assouline, Z., Barboni, P., Barel, O., Berutti, R., Bychkov, I., Caporali, L., et al. (2021). Impaired complex I repair causes recessive Leber's hereditary optic neuropathy. *J. Clin. Invest.* *131*, e138267.
49. Yu, J., Liang, X., Ji, Y., Ai, C., Liu, J., Zhu, L., Nie, Z., Jin, X., Wang, C., Zhang, J., et al. (2020). PRICKLE3 linked to ATPase biogenesis manifested Leber's hereditary optic neuropathy. *J. Clin. Invest.* *130*, 4935–4946.
50. Baig, S.S., Strong, M., Rosser, E., Taverner, N.V., Glew, R., Miedzybrodzka, Z., Clarke, A., and Craufurd, D. (2017). 22 Years of predictive testing for Huntington's disease: the experience of the UK Huntington's Prediction Consortium. *Eur. J. Hum. Genet.* *25*, 1290.

The American Journal of Human Genetics, Volume 108

Supplemental information

Establishing risk of vision loss in

Leber hereditary optic neuropathy


M. Isabel G. Lopez Sanchez, Lisa S. Kearns, Sandra E. Staffieri, Linda Clarke, Myra B. McGuinness, Wafaa Meteoukki, Sona Samuel, Jonathan B. Ruddle, Celia Chen, Clare L. Fraser, John Harrison, Alex W. Hewitt, Neil Howell, and David A. Mackey

Supplemental Data


Figure S1. Confirmation of heteroplasmic mutation in individuals from LHON pedigrees

NZ10, VIC02 and VIC30 by PCR and Sanger sequencing.

NZ10 pedigree (m.14484T>C)




NZ10-1




NZ10-2

VIC02 pedigree (m.14484T>C)




VIC2-3



VIC2-5

VIC30 pedigree (m.14484T>C)



VIC30-2

Table S1. Primer sequences of primers used for PCR

Primer	Sequence
11778_Fwd	CCC ACC TTG GCT ATC ATC
11778_Rev	GGT AAG GCG AGG TTA GCG
14484_Fwd	GCA TAA TTA AAC TTT ACT TC
14484_Rev	AGA ATA TTG AGG CGC CAT TG
3460_Fwd	TTC AAA TTC CTC CCT GTA CG
3460_Rev	GGC TAC TGC TCG CAG TG
DloopHV1_Fwd	TGG GGA AGC AGA TTT GGG TA
DloopHV1_Rev	ACG TGT GGG CTA TTT AGG CT
DloopHV2_Fwd	ATG GGC GGG GGT TGT ATT G
DloopHV2_Rev	CAC AGG TCT ATC ACC CTA TTA ACC

Table S2. Complete mtDNA Sequences of LHON Pedigrees

Sequences are presented as differences from the mtDNA revised Cambridge Reference Sequence (NC_012920.1). Expansions or contractions of simple repeat sequences in the mitochondrial genome are not shown. In addition to the pedigree, we specify the pathogenic LHON mutation and the mtDNA haplogroup according to PhyloTree¹.

Pedigree (mutation)	Haplogroup	mtDNA control region	mtDNA coding region
NSW01 (m.11778G>A)	H1n	146 T:C; 263 A:G; 16468 T:C; 16519 T:C	750 A:G; 1438 A:G; 2098 G:A; 3010 G:A; 4769 A:G; 8860 A:G; 14199 T:C; 15326 A:G; 15742 C:A; 15924 A:G
NSW03 (m.11778G>A)	U5a1	73 A:G; 263 A:G; 16256 C:T; 16270 C:T; 16293 A:G; 16399 A:G	750 A:G; 1438 A:G; 2706 A:G; 3197 T:C; 4769 A:G; 7028 C:T; 7792 C:T; 8860 A:G; 9477 G:A; 11467 A:G; 11719 G:A; 11914 G:A; 12308 A:G; 12372 G:A; 13617 T:C; 14766 C:T; 14793 A:G; 15218 A:G; 15317 G:A; 15326 A:G
NSW04 (m.11778G>A)	J1c1	73 A:G; 185 G:A; 228 G:A; 263 A:G; 295 C:T; 462 C:T; 482 T:C; 489 T:C; 16069 C:T; 16126 T:C	750 A:G; 1438 A:G; 2706 A:G; 3010 G:A; 3394 T:C; 4216 T:C; 4769 A:G; 7028 C:T; 8020 G:A; 8860 A:G; 10398 A:G; 11251 A:G; 11287 T:C; 11719 G:A; 12612 A:G; 13708 G:A; 14766 C:T; 14798 T:C; 15326 A:G; 15452 C:A
NSW06 (m.11778G>A)	H4a1	263 A:G	750 A:G; 1438 A:G; 3992 C:T; 4024 A:G; 4769 A:G; 5004 T:C; 8269 G:A; 8860 A:G; 9123 G:A; 10124 T:C; 14365 C:T; 14582 A:G; 14956 T:C; 15326 A:G
NSW09 (m.11778G>A)	J1c4	73 A:G; 185 G:A; 228 G:A; 263 A:G; 295 C:T; 462 C:T; 489 T:C; 16069 C:T; 16126 T:C	750 A:G; 1438 A:G; 2706 A:G; 3010 G:A; 4216 T:C; 4769 A:G; 7028 C:T; 7853 G:A; 8860 G:A; 9120 A:G; 9632 A:G; 9701 T:C; 10398 A:G; 11251 A:G; 11719 G:A; 12083 T:C; 12612 A:G; 13708 G:A; 14766 C:T; 14798 T:C; 15326 A:G; 15452 C:A
NSW11 (m.11778G>A)	Y2a	73 A:G; 263 A:G; 482 T:C; 16126 T:C; 16231 T:C; 16305 A:G; 16311 T:C; 16362 T:C	750 A:G; 1438 A:G; 2706 A:G; 4769 A:G; 5147 G:A; 5417 G:A; 6941 T:C; 7028 C:T; 7632 T:C; 7859 G:A; 8392 G:A; 8860 A:G; 10398 A:G; 11299 T:C; 11719 G:A; 12161 T:C; 12705 C:T; 14178 T:C; 14693 A:G; 14766 C:T; 14914 A:G; 15244 A:G; 15326 A:G
NSW17 (m.11778G>A)	T2f1	73 A:G; 195 T:C; 263 A:G; 16126 T:C; 16189 T:C; 16294 C:T; 16296 C:T; 16298 T:C; 16519 T:C	709 G:A; 750 A:G; 1438 A:G; 1888 G:A; 2706 A:G; 4216 T:C; 4769 A:G; 4917 A:G; 5277 T:C; 5426 T:C; 6489 C:A; 7028 C:T; 8270 C:T; 8697 G:A; 8860 A:G; 10463 T:C; 11251 A:G; 11719 G:A; 11812 A:G; 13368 G:A; 14233 A:G; 14323 G:A; 14766 C:T; 14905 G:A; 15043 G:A; 15326 A:G; 15452 C:A; 15607 A:G; 15928 G:A
NSW18 (m.11778G>A)	J1c1	73 A:G; 263 A:G; 295 C:T; 462 C:T; 482 T:C; 489 T:C; 16069 C:T; 16126 T:C	750 A:G; 1438 A:G; 2706 A:G; 3010 G:A; 3394 T:C; 4216 T:C; 4769 A:G; 7028 C:T; 8860 A:G; 10398 A:G; 11251 A:G; 11719 G:A; 12612 A:G; 13194 G:A;

NZ02 (m.11778G>A)	U5b2a1	73 A:G; 150 C:T; 152 T:C; 263 A:G; 16189 T:C; 16325 T:C	13708 G:A; 14766 C:T; 14798 T:C; 15326 A:G; 15452 C:A 750 A:G; 1438 A:G; 1721 C:T; 2706 A:G; 3197T:C; 4732 A:G; 4769 A:G; 6158 A:G; 7028 C:T; 7768 A:G; 8860 A:G; 9477 G:A; 11467 A:G; 11719 G:A; 12308 A:G; 12372 G:A; 13617 T:C; 13637 A:G; 14182 T:C; 14323 G:A; 14766 C:T; 15326 A:G
QLD02 (m.11778G>A)	J2b1	73 A:G; 150 C:T; 152 T:C; 263 A:G; 295 C:T; 489 T:C; 16069 C:T; 16126 T:C; 16193 C:T	750 A:G; 1438 A:G; 2706 A:G; 2789 C:T; 4216 T:C; 4769 A:G; 5633 C:T; 7028 C:T; 7476 C:T; 8860 A:G; 9872 A:G; 10172 G:A; 10398 A:G; 11251 A:G; 11719 G:A; 12612 A:G; 13708 G:A; 13821 C:T; 14766 C:T; 15257 G:A; 15326 A:G; 15452 C:A; 15812 G:A
QLD03 (m.11778G>A)	J1c2	73 A:G; 185 G:A; 188 A:G; 228 G:A; 263 A:G; 295 C:T; 462 C:T; 489 T:C; 16069 C:T; 16126T:C	750 A:G; 1438 A:G; 2706 A:G; 3010 G:A; 4216 T:C; 4769 A:G; 6269 A:C; 7028 C:T; 8860 A:G; 10398 A:G; 11251 A:G; 11719 G:A; 12612 A:G; 13708 G:A; 14766 C:T; 14798 T:C; 15326 A:G; 15452 C:A
QLD04 (m.11778G>A)	T2b4	73 A:G; 263 A:G; 16126 T:C; 16294 C:T; 16304 T:C; 16519 T:C	709 G:A; 750 A:G; 930 G:A; 1438 A:G; 1888 G:A; 2706 A:G; 4216 T:C; 4769 A:G; 4917 A:G; 7028 C:T; 8697 G:A; 8860 A:G; 9254 A:G; 10463 T:C; 11251 A:G; 11719 G:A; 11812 A:G; 13368 G:A; 14233 A:G; 14766 C:T; 14905 G:A; 15326 A:G; 15452 C:A; 15607 A:G; 15928 G:A
TAS01 ^a (m.11778G>A)	H	152 T:C; 263 A:G; 16093 T:C	750 A:G; 1438 A:G; 4626 A:G; 4769 A:G; 8860 A:G; 11788 C:T; 15317 G:A; 15326 A:G
TAS05 (m.11778G>A)	H3f	93 A:G; 263 A:G; 16153 G:A; 16311 T:C; 16519 T:C	750 A:G; 1438 A:G; 4769 A:G; 6776 T:C; 8860 A:G; 12811 T:C; 15326 A:G
VIC04 (m.11778G>A)	H1c3	195 T:C; 257 A:G; 263 A:G; 477 T:C; 16290 C:T; 16519 T:C	750 A:G; 1438 A:G; 3010 G:A; 4769 A:G; 8473 T:C; 8860 A:G; 15326 A:G
VIC05 (m.11778G>A)	K2a4	73 A:G; 146 T:C; 152 T:C; 263 A:G; 16129 G:A; 16224 T:C; 16311 T:C; 16519 T:C	709 G:A; 750 A:G; 1438 A:G; 1811 A:G; 2706 A:G; 3480 A:G; 4561 T:C; 4769 A:G; 7028 C:T; 8860 A:G; 9055 G:A; 9698 T:C; 9716 T:C; 10550 A:G; 11299 T:C; 11467 A:G; 11549 C:T; 11719 G:A; 12308 A:G; 12372 G:A; 14167 C:T; 14766 C:T; 14798 T:C; 15326 A:G
VIC06 (m.11778G>A)	H1	152 T:C; 263 A:G; 16189 T:C; 16239 C:T; 16519 T:C	750 A:G; 1438 A:G; 3010 G:A; 4769 A:G; 8860 A:G; 11596 A:G; 13230 C:T; 13768 T:C; 15326 A:G
VIC07 (m.11778G>A)	l2a	73 A:G; 152 T:C; 199 T:C; 204 T:C; 207 G:A; 250 T:C; 263 A:G; 16129 G:A; 16145 G:A; 16223 C:T; 16391 G:A; 16519 T:C	750 A:G; 1438 A:G; 1719 G:A; 2706 A:G; 4529 A:T; 4769 A:G; 7028 C:T; 7813 C:T; 8251 G:A; 8860 A:G; 9266 G:A; 10034 T:C; 10238 T:C; 10398 A:G; 11065 A:G; 11719 G:A; 12501 G:A; 12705 C:T; 13780 A:G; 14766 C:T; 15043 G:A; 15326 A:G; 15758 A:G; 15924 A:G; 15937 A:G
VIC10 (m.11778G>A)	J2a1a	73 A:G; 150 C:T; 152 T:C; 195 T:C 198 C:T; 222 C:T; 263 A:G; 295	750 A:G; 1438 A:G; 1587 T:C; 2706 A:G; 4216 T:C; 4769 A:G; 7028 C:T; 7476 C:T; 7789 G:A; 8860 A:G; 10398

VIC17 (m.11778G>A)	J1c5a	C:T; 319 T:C; 489 T:C; 513 G:A; 16069 C:T; 16126 T:C; 16145 G:A; 16189 T:C; 16231 T:C; 16261 C:T 73 A:G; 150 C:T; 185 G:A; 228 G:A; 263 A:G; 295 C:T; 462 C:T; 489 T:C; 16069 C:T; 16126 T:C; 16519 T:C	A:G; 10499 A:G; 11251 A:G; 11377 G:A; 11581 A:T; 11719 G:A; 12279 A:G ^c ; 12612 A:G; 13708 A:G; 13722 A:G; 14133 A:G; 14766 C:T; 15257 G:A; 15326 A:G; 15452 C:A 750 A:G; 1438 A:G; 2387 T:C; 2706 A:G; 3010 G:A; 4216 T:C; 4769 A:G; 5198 A:G; 7028 C:T; 8860 A:G; 10192 C:T; 10398 A:G; 11251 A:G; 11719 G:A; 12612 A:G; 13708 G:A; 14766 C:T; 14798 T:C; 15326 A:G; 15452 C:A
VIC18 (m.11778G>A)	U4c1	73 A:G; 195 T:C; 263 A:G; 489 T:C; 499 G:A; 16169 C:T; 16179 C:T; 16234 C:T; 16356 T:C; 16519 T:C	750 A:G; 1438 A:G; 1811 A:G; 2706 A:G; 4646 T:C; 4769 A:G; 4811 A:G; 5999 T:C; 6047 A:G; 6146 A:G; 7028 C:T; 8860 A:G; 9070 T:G; 10907 T:C; 11009 T:C; 11332 C:T; 11467 A:G; 11719 G:A; 12308 A:G; 12372 G:A; 14620 C:T; 14766 C:T; 14866 C:T; 15326 A:G; 15693 T:C
VIC19 (m.11778G>A)	B4b1a2	73 A:G; 207 G:A; 263 A:G; 499 G:A; 16136 T:C; 16153 G:A; 16189 T:C; 16217 T:C; 16235 A:G; 16519 T:C	750 A:G; 827 A:G; 1438 A:G; 1664 G:A; 2706 A:G; 4769 A:G; 4820 G:A; 6023 G:A; 6216 T:C; 6413 T:C; 7028 C:T; 8860 A:G; 11719 G:A; 13590 G:A; 14766 C:T; 15326 A:G; 15535 C:T
VIC21 (m.11778G>A)	H13a1a	152 T:C; 263 A:G; 16311 T:C	750 A:G; 1438 A:G; 2259 A:G; 3591 G:T; 4745 A:G; 4769 A:G; 8860 A:G; 9233 T:C; 11410 T:C; 13680 C:T; 14872 C:T; 15326 A:G
VIC22 (m.11778G>A)	H13a1a	263 A:G	750 A:G; 1438 A:G; 2259 A:G; 4745 A:G; 4769 A:G; 8860 A:G; 13680 C:T; 14872 C:T; 15326 A:G; 15355 G:A
VIC25 (m.11778G>A)	T1a1	73 A:G; 152 T:C; 195 T:C; 263 A:G; 16126 T:C; 16163 A:G; 16172 T:C; 16186 C:T; 16189 T:C; 16294 C:T; 16304 T:C; 16519 T:C	709 G:A; 750 A:G; 1438 A:G; 1888 G:A; 2706 A:G; 4216 T:C; 4769 A:G; 4917 A:G; 7028 C:T; 7269 G:A; 8967 G:A; 8860 A:G; 9443 T:C; 9899 T:C; 10463 T:C; 10646 G:A; 11251 A:G; 11719 G:A; 12432 C:T; 12633 C:A; 13368 G:A; 14766 C:T; 14905 G:A; 15326 A:G; 15452 C:A; 15607 A:G; 15928 G:A
VIC29 (m.11778G>A)	U5a1a1	73 A:G; 263 A:G; 16256 C:T; 16270 C:T; 16399 A:G	750 A:G; 1438 A:G; 1700 T:C; 2706 A:G; 3197 T:C; 4769 A:G; 5495 T:C; 6905 A:G; 7028 C:T; 8860 A:G; 9477 G:A; 11467 A:G; 11719 G:A; 12308 A:G; 12372 G:A; 13015 T:C; 13617 T:C; 14599 A:G; 14766 C:T; 14793 A:G; 15218 A:G; 15326 A:G; 15924 A:G
WAU03 (m.11778G>A)	l2a	73 A:G; 152 T:C; 199 T:C; 204 T:C; 207 G:A; 250 T:C; 263 A:G; 16126 T:C; 16145 G:A; 16223 C:T; 16391 G:A; 16519 T:C	750 A:G; 1438 A:G; 1719 G:A; 2706 A:G; 3398 T:C; 4529 A:T; 4769 A:G; 7028 C:T; 8251 G:A; 8860 A:G; 10034 T:C; 10238 T:C; 10398 A:G; 11065 A:G; 11719 G:A; 12501 G:A; 12705 C:T; 13780 A:G; 14766 C:T; 15043 G:A; 15326 A:G; 15758 A:G; 15924 A:G
WAU04 (m.11778G>A)	H3	263 A:G; 16189 T:C; 16519 T:C	750 A:G; 1438 A:G; 4769 A:G; 5087 T:C; 6776 T:C; 8860 A:G; 10325 G:A; 15326 A:G
NSW12 (m.14484T>C)	K1c2	73 A:G; 146 T:C; 152 T:C; 263 A:G; 16224 T:C; 16311 T:C; 16320	750 A:G; 1189 T:C; 1438 A:G; 1811 A:G; 2706 A:G; 3480 A:G; 4769 A:G; 7028 C:T; 8860 A:G; 9006 A:G; 9055 G:A; 9698 T:C; 10398 A:G; 10550 A:G;

		C:T; 16356 T:C; 16519 T:C	11299 T:C; 11467 A:G; 11719 G:A; 12308 A:G; 12372 G:A; 14002 A:G; 14040 G:A; 14167 C:T; 14766 C:T; 14798 T:C; 15326 A:G
NSW15 (m.14484T>C)	U5a1a1	73 A:G; 263 A:G; 16256 C:T; 16270 C:T; 16399 A:G	750 A:G; 979 C:T; 1438 A:G; 1700 T:C; 2706 A:G; 3197 T:C; 4769 A:G; 5495 T:C; 6164 C:T; 7028 C:T; 8860 A:G; 9477 G:A; 11467 A:G; 11719 G:A; 12308 A:G; 12372 G:A; 13617 T:C; 14766 C:T; 14793 A:G; 15218 A:G; 15326 A:G; 15924 A:G
NSW19 (m.14484T>C)	L1b1a1	73 A:G; 152 T:C; 182 C:T; 185 G:T; 195 T:C; 247 G:A; 263 A:G; 264 C:T; 357 A:G; 16114 C:T; 16126 T:C; 16187 C:T; 16189 T:C; 16215 A:C; 16223 C:T; 16264 C:T; 16270 C:T; 16278 C:T; 16293 A:G; 16311 T:C; 16519 T:C	709 G:A; 710 T:C; 750 A:G; 769 G:A; 825 T:A; 1018 G:A; 1738 T:C; 2352 T:C; 2706 A:G; 2758 G:A; 2768 A:G; 2885 T:C; 3308 T:C; 3396 T:C; 3594 C:T; 3666 G:A; 3693 G:A; 4104 A:G; 4769 A:G; 5036 A:G; 5046 G:A; 5393 T:C; 5655 T:C; 6548 C:T; 6827 T:C; 6989 A:G; 7028 C:T; 7055 A:G; 7146 A:G; 7256 C:T; 7389 T:C; 7521 G:A; 7867 C:T; 8248 A:G; 8468 C:T; 8655 C:T; 8701 A:G; 8860 A:G; 9540 T:C; 10398 A:G; 10688 G:A; 10810 T:C; 10873 T:C; 11719 G:A; 12519 T:C; 12705 C:T; 13105 A:G; 13506 C:T; 13650 C:T; 13789 T:C; 13880 C:A; 14178 T:C; 14203 A:G; 14560 G:A; 14766 C:T; 14769 A:G; 15115 T:C; 15326 A:G
TAS02 (m.14484T>C)	J1c2c	73 A:G; 146 T:C; 185 G:A; 188 A:G; 222 C:T; 228 G:A; 263 A:G; 295 C:T; 462 C:T; 489 T:C; 16069 C:T; 16126 T:C; 16261 C:T; 16519 T:C	750 A:G; 1438 A:G; 2706 A:G; 3010 G:A; 4216 T:C; 4769 A:G; 7028 C:T; 8610 T:C; 8860 A:G; 10398 A:G; 10685 G:A; 11251 A:G; 11719 A:G; 12612 A:G; 13281 T:C; 13708 G:A; 13933 A:G; 14766 C:T; 14798 T:C; 15326 A:G; 15452 C:A
VIC02 ^b (m.14484T>C)	J1b1a	73 A:G; 185 G:A; 242 C:T; 263 A:G; 295 C:T; 462 C:T; 489 T:C; 16069 C:T; 16126 T:C; 16145 G:A; 16172 T:C; 16222 C:T; 16261 C:T	750 A:G; 1438 A:G; 1462 G:A; 2158 A:G; 2706 A:G; 3010 G:A; 4216T:C; 4659 G:A; 4769 A:G; 5460 C:T; 6345 T:C; 7028 G:A; 7299 A:G; 8269 G:A; 8557 G:A; 8860 A:G; 10398 A:G; 11251 A:G; 11719 A:G; 12007 G:A; 12612 A:G; 13708 G:A; 13879 T:C; 14766 C:T; 15326 T:C; 15452 C:A
VIC08 (m.14484T>C)	J1c1	73 A:G; 152 T:C; 263 A:G; 295 C:T; 462 C:T; 489 T:C; 16069 C:T; 16126 T:C; 16193 C:T; 16519 T:C	750 A:G; 1438 A:G; 2706 A:G; 3010 G:A; 4216 T:C; 4769 A:G; 7028 C:T; 7789 G:A; 7963 A:G; 8779 C:T; 8860 A:G; 9041 A:G; 10398 A:G; 11251 A:G; 11719 G:A; 12612 A:G; 12681 T:C; 13708 G:A; 14766 C:T; 15326 A:G; 15452 C:A
VIC11 (m.14484T>C)	J1c1	73 A:G; 185 G:A; 189 A:G; 228 G:A; 263 A:G; 295 C:T; 462 C:T; 489 T:C; 16069 C:T; 16126 T:C; 16293 A:G	750 A:G; 1438 A:G; 2706 A:G; 3010 G:A; 3394 T:C; 4216 T:C; 4769 A:G; 7028 C:T; 8860 A:G; 10398 A:G; 11251 A:G; 11719 G:A; 12612 A:G; 13708 G:A; 14766 C:T; 14798 T:C; 15184 T:C; 15326 A:G; 15452 C:A
VIC14 (m.14484T>C)	H3c	195 T:C; 263 A:G; 16176 C:T	750 A:G; 1211 G:A; 1438 A:G; 4769 A:G; 6261 G:A; 6776 T:C; 7444 G:A; 8347 A:G; 8860 A:G; 12957 T:C; 14305 G:A; 15326 A:G

TAS03 (m.3460G>A)	H5a1	263 A:G; 456 C:T; 16304 T:C	750 A:G; 1438 A:G; 4336 T:C; 4769 A:G; 8860 A:G; 12696 T:C; 15326 A:G; 15833 C:T
VIC01 (m.3460G>A)	H	93 A:G; 207 G:A; 263 A:G; 16519 T:C	750 A:G; 1438 A:G; 4769 A:G; 8860 A:G; 9612 G:A; 11560 A:G; 15058 C:T; 15326 A:G
WAU06 (m.3460G>A)	M53	73 A:G; 240 A:G; 263 A:G; 390 A:T; 438 C:T; 489 T:C; 16051 A:G; 16093 T:C; 16223 C:T; 16316 A:G; 16400 C:T; 16519 T:C	593 T:C; 750 A:G; 2010 T:C; 2706 A:G; 4769 A:G; 5493 T:C; 5821 G:A; 6216 T:C; 6719 T:C; 7028 C:T; 7805 G:A; 8701 A:G; 8860 A:G; 9302 C:T; 9540 T:C; 10084 T:C; 10398 A:G; 10400 C:T; 10873 T:C; 11167 A:G; 11560 A:G; 11719 G:A; 12630 G:A; 12705 C:T; 14766 C:T; 14783 T:C; 15043 G:A; 15301 G:A; 15315 C:T; 15326 A:G
NSW08 (m.14482C>G)	I1a	73 A:G; 199 T:C; 204 T:C; 250 T:C; 263 A:G; 16129 G:A; 16172 T:C; 16223 C:T; 16311 T:C; 16391 G:A; 16519 T:C	750 A:G; 1438 A:G; 1531 C:T; 1719 G:A; 2706 A:G; 3447 A:G; 4529 A:T; 4769 A:G; 6734 G:A; 7028 C:T; 8248 A:G; 8251 G:A; 8616 G:T; 8860 A:G; 9966 G:A; 10034 T:C; 10238 T:C; 10398 A:G; 10550 A:G; 11719 G:A; 12501 G:A; 12705 C:T; 12864 T:C; 13780 A:G; 14766 C:T; 15043 G:A; 15326 A:G; 15589 C:T
VIC20 (m.11778G>A/ m.14484T>C)	U5a1a1	73 A:G; 152 T:C; 263 A:G; 16231 T:C; 16256 C:T; 16270 C:T; 16399 A:G	750 A:G; 1438 A:G; 1700 T:C; 2706 A:G; 3197 T:C; 4769 A:G; 5495 T:C; 7028 C:T; 8860 A:G; 9477 G:A; 11467 A:G; 11719 G:A; 12308 A:G; 12372 G:A; 12771 G:A; 13617 T:C; 14766 C:T; 14793 A:G; 15218 A:G; 15326 A:G; 15924 A:G
QLD01 (m.14484T>C/ m.4160T>C)	U4a1a	73 A:G; 152 T:C; 263 A:G; 499 G:A; 16134 C:T; 16356 T:C; 16519 T:C	750 A:G; 961 T:C; 1438 A:G; 1811 A:G; 2706 A:G; 4646 T:C; 4769 A:G; 5999 T:C; 6047 A:G; 6845 C:T; 7028 C:T; 8818 C:T; 8860 A:G; 11332 C:T; 11467 A:G; 11719 G:A; 12308 A:G; 12372 G:A; 12937 A:G; 14620 C:T; 14766 C:T; 15326 A:G; 15693 T:C

^a Nine members of the TAS01 pedigree were used for sequencing; five of them were sequenced in triplicate. Within the limits of MitoChip-based sequencing, all sequences matched those obtained previously by both manual and automated sequencing procedures.

^b Sequence change is heteroplasmic in the sample analyzed.

Table S3. Partial mtDNA Sequences of LHON Pedigrees.

Sequences are presented as differences from the mtDNA revised Cambridge Reference Sequence (NC_012920.1). Expansions or contractions of simple repeat sequences in the mitochondrial genome are not shown. In addition to the pedigree, we specify the pathogenic LHON mutation and the mtDNA haplogroup according to MitoMaster².

Pedigree (mutation)	Haplogroup	mtDNA control region	mtDNA coding region
NSW02 (m.11778G>A)	H	152 T:C; 263 A:G; 16189 T:C; 16239 C:T; 16519 T:C	4769 A:G; 13768 T:C
NSW23 (m.11778G>A)	J	73 A:G; 150 C:T; 152 T:C; 195 T:C; 215 A:G; 263 A:G; 295 C:T; 319 T:C; 489 T:C; 513 G:A; 16069 C:T; 16126 T:C; 16145 G:A; 16231 T:C; 16261 C:T	3447 A:G; 4216 T:C; 4769 A:G; 7419 G:A; 7476 C:T; 11251 A:G; 11719 G:A; 12612 A:G; 13708 G:A; 13722 A:G; 15257 G:A
NSW26 (m.11778G>A)	K	73 A:G; 146 T:C; 152 T:C; 263 A:G; 16224 T:C; 16259 C:T; 16311 T:C; 16320 C:T; 16519 T:C	3480 A:G; 11299 T:C; 11467 A:G; 11719 G:A
NZ01 (m.11778G>A)	U	73 A:G; 152 T:C; 217 T:C; 263 A:G; 508 A:G; 16051 A:G; 16092 T:C; 16129 G:C; 16189 T:C; 16362 T:C; 16519 T:C	11719 G:A
NZ03 (m.11778G>A)	J	73 A:G; 185 G:A; 188 A:G; 228 G:A; 263 A:G; 295 C:T; 462 C:T; 489 T:C; 16069 C:T; 16126 T:C; 16325 T:C; 16519 T:C	4216 T:C; 4769 A:G; 11719 G:A; 11911 T:C; 12612 A:G; 13708 G:A; 14798 T:C
NZ12 (m.11778G>A)	H	74 T:A; 263 A:G; 315 C:CC; 16337 C:A; 16519 T:C	
QLD05 (m.11778G>A)	HV	263 A:G; 16111 C:T; 16519 T:C	
QLD10 (m.11778G>A)	N	73 A:G; 204 T:C; 263 A:G; 16223 C:T	
QLD11 (m.11778G>A)	W	73 A:G; 195 T:C; 204 T:C; 207 G:A; 263 A:G; 16223 C:T; 16292 C:T	3505 A:G; 11719 G:A
QLD12 (m.11778G>A)	U	195 T:C; 263 A:G; 16192 C:T; 16256 C:T; 16270 C:T; 16320 C:T; 16399 A:G	11467 A:G
VIC03 (m.11778G>A)	U	16192 C:T; 16249 T:C; 16270 C:T; 16311 T:C; 16411 C:G; 16412 G:T	11440 G:A; 11467 A:G; 11719 G:A
VIC31 (m.11778G>A)	J	16069 C:T; 16126 T:C; 16311 T:C; 16411 C:G; 16412 G:T	
VIC41 (m.11778G>A)	H	152 T:C; 263 A:G; 16093 T:C	11719 G:A
VIC43 (m.11778G>A)	K	73 A:G; 114 C:T; 263 A:G; 315 C:CC; 16224 T:C; 16234 C:T; 16311 T:C	11299 T:C; 11467 A:G; 11470 A:G; 11719 G:A
WAU01 (m.11778G>A)	J	73 A:G; 228 G:A; 263 A:G; 295 C:T; 462 C:T; 482 T:C; 489 T:C; 16069 C:T	3394 T:C; 4216 T:C; 4769 A:G; 11251 A:G; 11719 G:A; 12612 A:G; 13708 G:A; 13899 T:C; 14798 T:C

WAU02 (m.11778G>A)	K	73 A:G; 150 C:T; 263 A:G; 315 C:CC; 16224 T:C; 16311 T:C; 16519 T:C	T11299C, A11467G, T11485C, G11719A, C11840T
ACT01 (m.14484T>C)	J	73 A:G; 185 G:A; 228 G:A; 263 A:G; 295 C:T; 462 C:T; 482 T:C; 489 T:C; 16069 C:T; 16126 T:C; 16213 T:C	3394 T:C; 4216 T:C; 4769 A:G; 9682 T:C; 11251 A:G; 11719 G:A; 12612 A:G; 13708 G:A
NZ10 ^a (m.14484T>C)	J	150 C:T; 152 T:C; 195 T:C; 215 A:G; 295 C:T; 319 T:C; 16126 T:C; 16145 G:A; 16231 T:C; 16261 C:T	11251 A:G; 11377 G:A
NZ11 (m.14484T>C)	J	150 C:T; 185 G:A; 228 G:A; 295 C:T; 462 C:T; 16126 T:C; 16311 T:C	
SAU05 (m.14484T>C)	H	195 T:C; 263 A:G; 310T:C; 366 G:A; 16448 T:C	11719 G:A
VIC30 ^a (m.14484T>C)	H	153 A:G; 195 T:C; 263 A:G	14299 T:A; 14487 T:G; 14488 T:G
VIC42 (m.14484T>C)	J	73 A:G; 185 G:A; 228 G:A; 263 A:G 295 C:T; 309 C:CCT; 310 T:C; 462 C:T; 482 T:C; 16126 T:C; 16213 G:A	14484 T:C; 14766 C:T; 14798 T:C
NSW07 (m.3460G>A)	T	73 A:G; 263 A:G; 331 A:G; 16126 T:C; 16234 T:C; 16294 C:T; 16296 C:T; 16519 T:C	4216 T:C; 4769 A:G; 4917 A:G; 11251 A:G; 11719 G:A; 11812 A:G; 13965 T:C; 13966 A:G; 14687 A:G; 15928 G:A
VIC28 (m.3460G>A)	H	114 C:T; 146 T:C; 195 T:C; 16288 T:C; 16302 A:G; 16362 T:C	
SAU04 (m.4171C>A)	HV0	72 T:C; 263 A:G; 195 T:C; 16497 A:G	

^a Sequence change is heteroplasmic in the sample analysed.

Table S4. Updated Assignments of Australian LHON Matrilineal Pedigrees

Previous Assignment	Updated Assignment	Reference
NSW13 (m.14484T>C)	NSW19 ^a	
NSW21(m.11778G>A)	VIC29 ^{a, b}	
QLD08 (m.14484T>C)	TAS02 ^b	
SAU01 (m.11778G>A)	NSW23 ^b	Chan <i>et al.</i> ³
TAS04	None OPA1 ^c	Mackey and Buttery ⁴
VIC12	None ^d	
VIC13 (m.11778G>A)	VIC04 ^b	
VIC16 (m.11778G>A)	TAS01 ^{a, b}	
VIC23 (m.11778G>A)	TAS01 ^{a, b}	
VIC26 (m.11778G>A)	TAS01 ^{a, b}	
VIC27 (m.11778G>A)	TAS01 ^b	
VIC44 (m.14484T>C)	TAS02 ^b	

^a Reassignment was made on the basis of mtDNA sequence analysis.

^b Confirmed or determined by further genealogical analysis.

^c Updated diagnosis of autosomal dominant optic atrophy

^d Determination of the complete mtDNA sequence from one family member failed to reveal a LHON mutation. As a result, no assignment is made pending further investigation.

Table S5. mtDNA haplogroup distribution amongst asymptomatic and affected individuals

mtDNA Haplotype	Mutation, number (%)							Total
	11778	14484	3460	14484/ 4160	14482	14484/ 11778	4171	
	n=3,986	n=1,215	n=176	n=84	n=54	n=41	n=12	n=5,568
H	2,699 (67.7)	98 (8.1)	128 (72.7)				12 (100)	2,937 (52.7)
J	495 (12.4)	934 (76.9)						1,429 (25.7)
U	241 (6.0)	26 (2.1)		84 (100)		41 (100)		392 (7.0)
I	126 (3.2)				54 (100)			180 (3.2)
K	97 (2.4)	67 (5.5)						164 (2.9)
L		54 (4.4)						54 (1.0)
T	29 (0.7)		10 (5.7)					39 (0.7)
B	23 (0.6)							23 (0.4)
M			16 (9.1)					16 (0.3)
N	16 (0.4)							16 (0.3)
Y	14 (0.4)							14 (0.3)
W	7 (0.2)							7 (0.1)
Unknown	239 (6.0)	36 (3.0)	22 (12.5)					297 (5.3)
Vision loss								
Carrier	3,586 (90.0)	1,089 (89.6)	155 (88.1)	23 (27.4)	47 (87.0)	38 (92.7)	10 (83.3)	4,948 (88.9)
Affected	400 (10.0)	126 (10.4)	21 (11.9)	61 (72.6)	7 (13.0)	3 (7.3)	2 (16.7)	620 (11.1)

Table S6. Vision loss in offspring of affected women

	Pedigree_Mother ID	Individuals with vision loss/ Total offspring over 25 years old; [penetrance]	
	m.11778G>A	Male	Female
1	ACT02_210411	0/1	0/1
2	ACT02_210414	1/1	0/0
3	NSW01_177394	0/0	0/2
4	NSW02_173447	0/0	0/2
5	NSW03_107116	0/1	1/2
6	NSW03_107118	0/0	0/2
7	NSW04_177055	1/2	1/1
8	NSW04_177163	0/1	0/1
9	NSW04_177157	1/2	0/0
10	NSW04_177052	1/3	0/0
11	NSW04_177060	2/2	0/1
12	NSW04_177117	0/1	0/2
13	NSW04_210438	2/4	0/6
14	NSW05_177864	1/3	0/1
15	NSW06_177316	0/2	0/1
16	NSW06_177330	0/0	0/1
17	NSW06_177338	0/1	0/1
18	NSW09_107204	0/3	1/2
19	NSW09_107215	1/3	0/2
20	NSW09_107201	1/4	0/2
21	NSW09_107232	0/1	0/0
22	NSW09_107254	1/1	0/0
23	NSW11_177475	1/2	0/1
24	NSW20_107993	2/2	1/1
25	NSW20_107997	1/1	0/0
26	NZ02_178125	1/2	0/0
27	NZ02_178126	1/2	0/1
28	QLD02_108797	0/0	0/1
29	QLD02_108510	0/2	0/7
30	VIC21_108837	0/1	0/3
31	VIC21_107370	0/3	0/2
32	QLD12_197430	0/0	0/1
33	TAS01_105409	1/1	1/1
34	TAS01_104842	0/2	0/0
35	TAS01_105041	1/1	0/4
36	TAS01_105245	0/1	2/2
37	TAS01_104467	1/3	0/7
38	TAS01_105011	2/2	0/2
39	TAS01_105194	0/2	0/1
40	TAS01_105223	0/2	0/2
41	TAS01_105255	0/0	0/3
42	TAS01_174915	3/3	0/1
43	TAS01_174813	0/0	0/2
44	TAS01_174490	0/0	0/2
45	TAS01_174090	0/1	0/1
46	TAS01_174449	1/3	0/4
47	TAS01_174824	0/2	0/0
48	VIC06_109398	1/4	1/5
49	VIC06_109401	0/1	0/1
50	VIC10_156049	0/1	0/0
51	VIC40_178503	1/2	0/1
52	WA01_107453	1/2	0/0
53	WA01_107435	0/0	1/1

54	WA01_107426	0/0	1/3
55	WA02_195793	0/2	0/0
56	WA04_109455	0/1	0/1
<hr/>			
m.14484T>C			
57	NSW19_107852	0/2	0/1
58	SA02_178275	1/2	0/0
59	TAS02_175792	0/0	0/3
60	TAS02_175621	0/1	0/0
61	TAS02_175743	0/1	0/2
62	TAS02_175324	0/0	0/2
63	TAS02_172941	1/2	0/1
64	TAS02_206147	0/0	0/1
65	TAS02_173057	0/6	0/3
66	VIC02_109179	0/0	3/3
67	VIC02_109183	0/1	0/0
68	VIC11_109070	0/1	0/2
69	VIC11_109069	0/0	1/2
70	VIC11_108996	1/3	1/1
<hr/>			
m.3460G>A			
71	VIC01_108975	0/0	1/2
72	NSW07_171660	0/1	0/1
<hr/>			
m.14484T>C + m.4160T>C			
73	QLD01_108448	0/0	1/1
74	QLD01_108424	2/2	1/2
75	QLD01_108446	2/2	1/1
76	QLD01_108491	1/3	1/1
77	QLD01_108444	0/3	0/1
78	QLD01_108437	1/1	1/1
79	QLD01_108463	1/1	2/2
80	QLD01_108495	0/0	1/1
81	QLD01_108474	1/1	0/0
82	QLD01_108469	1/1	4/4
83	QLD01_108473	0/0	2/2
84	QLD01_108421	0/1	1/1
85	QLD01_108439	1/1	0/0
86	QLD01_108412	3/4	4/6
87	QLD01_108441	0/0	2/2
88	QLD01_108451	0/0	1/1
89	QLD01_108454	0/0	1/1
90	QLD01_108456	1/3	0/0
91	QLD01_108466	1/1	2/2
92	QLD01_108488	0/0	1/1
93	QLD01_108493	0/0	1/2
<hr/>			
m.14482C>G			
94	NSW08_108088	1/1	1/2
<hr/>			
Total		49/132	44/149
		[37.1%]	[29.5%]

Supplemental Method

Participant recruitment

In 1990, Professor David Mackey (DM) contacted all ophthalmologists in Tasmania and all organisations for the blind in Australia asking to be put in contact with any patient affected by LHON. In addition, DM contacted all clinicians and researchers who had published on LHON pedigrees in Australia. LHON family members were asked to provide their matrilineal family tree as far back as possible, often with assistance of other family members. A professional genealogist then expanded each pedigree using national genealogical resources such as the digitised and microfilmed births deaths and marriage records, published family trees and histories available at genealogical society libraries, as well as legal documents such as wills that name living descendants. Many smaller families were subsequently linked into the main pedigrees ⁴.

Subsequently, DM contacted every ophthalmologist in Australia and offered DNA testing for patients suspected to be affected by LHON. This identified some new branches of the main families and provided additional updated pedigree information as well as new mainly small families³. Since 1995, LHON patients and families have been referred to our clinics in Melbourne, Tasmania and Western Australia by ophthalmologists across Australia, and new patients have also self-referred to our research team or clinics. In addition to genealogical linkage investigations, we use mtDNA sequencing to identify related pedigrees and conduct more exhaustive genealogical searches to confirm potential linkages. We provide national genetic counselling advice to LHON families.

Supplemental References

1. van Oven, M., and Kayser, M. (2009). Updated comprehensive phylogenetic tree of global human mitochondrial DNA variation. *Hum Mutat* 30, E386-394.
2. Lott, M.T., Leipzig, J.N., Derbeneva, O., Xie, H.M., Chalkia, D., Sarmady, M., Procaccio, V., and Wallace, D.C. (2013). mtDNA Variation and Analysis Using Mitomap and Mitomaster. *Curr Protoc Bioinformatics* 44, 1.23.21-26.
3. Chan, C., Mackey, D.A., and Byrne, E. (1996). Sporadic Leber hereditary optic neuropathy in Australia and New Zealand. *Aust N Z J Ophthalmol* 24, 7-14.
4. Mackey, D.A., and Buttery, R.G. (1992). Leber hereditary optic neuropathy in Australia. *Aust N Z J Ophthalmol* 20, 177-184.